Abcam, ab269312, Alexa Fluor® 700 Anti-CD22 antibody [IS7]

Size: 100Test
Mouse Monoclonal CD22 antibody - conjugated to Alexa Fluor® 700. Suitable for Flow Cyt and reacts with Human samples. Immunogen corresponding to Cell preparation containing CD22 protein.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:IS7,
Isotype:IgG1,
Conjugation:Alexa Fluor® 700,
Excitation/Emission:Ex: 702nm, Em: 723nm,
Carrier free:No,
Reacts with:Human,
Applications:Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Cell preparation containing CD22 protein. The exact immunogen used to generate this antibody is proprietary information.P20273,
Specificity:reacts with an extracellular epitope of CD22.

Product details:
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

Properties and Storage Information:
Form-Liquid, Purification technique-Size-exclusion chromatography, Purification notes-The purified antibody is conjugated with Alexa Fluor® 700 under optimum conditions. The conjugate is purified by size-exclusion chromatography., Storage buffer-pH: 7.4Preservative: 0.1% Sodium azideConstituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD22 also known as Siglec-2 or B-lymphocyte cell adhesion molecule (BL-CAM) is a transmembrane protein with a mass of around 140 kDa. It is selectively expressed on the surface of mature B cells and some immature B cells. This protein plays an important role in the immune system particularly in the regulation of B cell function. CD22 functions by modulating signal transduction processes through its cytoplasmic domain which contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs).
Biological function summary
CD22 acts mainly as a negative regulator of B cell receptor (BCR) signaling. It is part of a complex that interacts with the BCR and other accessory molecules. CD22 helps maintain B cell tolerance by inhibiting overactive signaling and preventing autoimmune responses. By binding to sialic acid-containing glycans CD22 modulates interactions between B cells and other cells aiding in the maintenance of immune homeostasis.
Pathways
CD22 plays a critical role in the BCR signaling pathway and the regulation of phosphatidylinositol 3-kinase (PI3K) signaling. It works together with proteins like CD19 and SHP-1 that are key components of these pathways. By influencing these signaling cascades CD22 contributes to the modulation of B cell activation proliferation and apoptosis ensuring proper functioning of the immune response.
CD22 is associated with autoimmune conditions and hematological malignancies such as hairy cell leukemia (HCL). Therapeutic approaches targeting CD22 such as anti-CD22 antibodies are being explored for treating these diseases. CD22's role in these conditions is connected with proteins involved in the autoimmune pathways or cancer development offering potential therapeutic targets for intervention.